Emmanuele Kouvousis/LinkedIn
Mar 31, 2026, 12:50
Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
Emmanuele Kouvousis, Non-Invasive Cardiologist, Scientific Director at Affidea, shared a post on LinkedIn:
“DOAC dose adjustments for older patients
In older adults, DOAC dose adjustment is largely driven by renal function, age, and low body weight.
Below is a concise, agent-specific summary based on the provided data.
General principles in older patients
- Bleeding risk is higher in older people with renal impairment, prompting cautious dosing and regular renal monitoring on DOACs.[1]
- For all DOACs, creatinine clearance (CrCl), not eGFR, should guide dosing.[1]
Apixaban (nonvalvular AF, renal impairment table)
- Standard: 5 mg twice daily if CrCl ≥30 mL/min and ABC rule not met.[1]
- Reduce to 2.5 mg twice daily if ≥2 of: age ≥80 years, body weight ≤60 kg, serum creatinine ≥133 µmol/L (applies across CrCl ≥30).[1]
- CrCl 15–29 mL/min: 2.5 mg twice daily.[1]
- CrCl <15: not recommended/contraindicated.[1]
Dabigatran (nonvalvular AF)
- Usual: 150 mg twice daily.[1]
- If age ≥80 years or concomitant verapamil: 110 mg twice daily.[1]
- If age 75–80, CrCl 30–50, GORD, or increase bleeding risk: consider 110 mg twice daily.[1]
- CrCl <30 mL/min: not recommended/contraindicated.[1]
- Bleeding and stroke risk both increase with age >75 years.[2]
Edoxaban (nonvalvular AF)
- Standard: 60 mg once daily for CrCl >50–95 mL/min.[3]
- 30 mg once daily if CrCl 15–50 mL/min or body weight ≤60 kg or selected P‑gp inhibitors.[3][1]
- CrCl >95 mL/min: do not use (reduced efficacy vs warfarin).[3]
- CrCl <15 mL/min: insufficient data/not recommended.[3]
Rivaroxaban (nonvalvular AF)
- CrCl >50 mL/min: 20 mg once daily with evening meal.[4]
- CrCl <50 mL/min (≥15): 15 mg once daily.[4][1]
- CrCl <15 mL/min or dialysis: not recommended.[4]
Monitoring in older adults
- At least annual renal and liver monitoring, more frequently when CrCl falls into the 30s or 20s (e.g., 3‑monthly, 2‑monthly).[1
References:
- Direct Oral Anticoagulant Dosing for Stroke Prevention in People with Nonvalvular Atrial Fibrillation and Renal
- Dabigatran (Pradaxa) – Geriatric Dosing and Uses
- Edoxaban (Savaysa) – Adult Dosing and Uses
- Rivaroxaban (Xarelto) – Adult Dosing and Uses“
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 15:26Mariusz Kruk: Plaque-Directed Intervention for the Prevention of Myocardial Infarction
-
Aug 21, 2026, 15:17Leveraging Data to Drive Sustainable Care for Haemophilia and Haemoglobinopathies – NNHF
-
Aug 21, 2026, 15:04Sex Differences in Platelet Function in Type 2 Diabetes – Seminars in Thrombosis and Hemostasis
-
Aug 21, 2026, 15:04Parth Parmar: RBC Morphology – A Practical Guide to Blood Smear Interpretation
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists